Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.

Oncotarget - 20 Oct 2015

Alshami Jad, Guiot Marie-Christine, Owen Scott, Kavan Petr, Gibson Neil, Solca Flavio, Cseh Agnieszka, Reardon David A, Muanza Thierry

Abstract excerpt

There are few effective treatments for recurrent glioblastoma multiforme (GBM). We present a patient with recurrent GBM who achieved a prolonged response to treatment with afatinib, an irreversible ErbB family blocker, plus temozolomide. A 58-year-old female patient was diagnosed with multifocal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to Dacarbazine

Share to Quinazolines

Share to Radiation-Sensitizing Agents

Share to Temozolomide

Source

Open in PubMed Open full text

Identifiers

PMID: 26423602
DOI: 10.18632/oncotarget.5297
PMCID: PMC4741824

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Prepared record publication-26423602-2026-09-05.1. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.PMID 26423602Read ↗

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.Semantic proximity Read ↗

Anlotinib plus Temozolomide for Recurrent Glioma: A Single-Center, Retrospective Study of 30 casesSemantic proximity Read ↗

Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification.Semantic proximity Read ↗

Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatmentSemantic proximity Read ↗

A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Semantic proximity Read ↗

Management of Asynchronous Multifocal Adult Glioblastoma with Loss of BRAFV600E-Mutant Clonality: A Case ReportSemantic proximity Read ↗

Predictive value of EGFR amplification and EGFRvIII mutation in EGFR-targeted therapy for recurrent glioblastoma: a systematic review.Semantic proximity Read ↗

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.Semantic proximity Read ↗

Widely metastatic glioblastoma with BRCA1 and ARID1A mutations: a case report.Semantic proximity Read ↗

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma.Semantic proximity Read ↗

Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation.Semantic proximity Read ↗

Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.